SAMHSA Ends Federal Funding for Fentanyl Test Strips, Leaving Ohio Public Health Agencies Scrambling

The landscape of American harm reduction policy shifted dramatically this week as federal guidance from the Substance Abuse and Mental Health Services Administration (SAMHSA) eliminated fentanyl test strips from the list of eligible supplies and services that can be purchased with agency funding. The change, which took effect without advance warning, has already forced public health agencies across Ohio to confront a stark reality: the primary funding stream for one of the most effective overdose prevention tools has evaporated at a moment when the nation is finally seeing sustained declines in drug mortality.

In Columbus, health department officials report they are burning through remaining supplies while desperately seeking alternative funding sources. The Franklin County Public Health Department had relied on SAMHSA grants to distribute tens of thousands of test strips annually through syringe service programs, community outreach teams, and mobile harm reduction units. Those distributions have slowed to a trickle. Staff who once handed out strips by the handful at encampments and drop-in centers now ration remaining inventory, calculating how long current supplies might last while state and local officials debate emergency appropriations.

The policy reversal arrives at a particularly cruel moment in the trajectory of the overdose crisis. After years of relentless increases that saw annual deaths climb past 110,000, the United States has recorded three consecutive years of declining mortality. Public health researchers attribute much of that progress to the widespread adoption of harm reduction strategies—including expanded naloxone distribution, the proliferation of medication-assisted treatment for opioid use disorder, and the growing availability of fentanyl test strips that allow people who use drugs to detect the presence of synthetic opioids before consumption.

The Mechanics of a Policy Shift

SAMHSA's guidance change did not emerge from congressional legislation or formal rulemaking. Rather, it appeared as an update to agency guidance on what constitutes permissible harm reduction activities under federal grant programs. The revision removes fentanyl test strips from the catalog of supplies that grantees may purchase with SAMHSA funds, effectively prohibiting their acquisition through the primary federal funding stream that supports harm reduction infrastructure nationwide.

The administrative nature of the change means it bypassed the public comment periods and regulatory reviews that typically accompany shifts in federal health policy. Grantees received notification through routine program guidance updates, leaving many scrambling to understand the implications for existing budgets and service delivery plans. For organizations with multi-year SAMHSA grants, the prohibition raises complex questions about whether remaining funds can be redirected or whether grant terms must be renegotiated entirely.

The timing coincides with broader transitions in federal drug policy under the Trump administration, which has signaled intentions to shift resources away from harm reduction approaches toward enforcement and abstinence-based treatment models. While the administration has not publicly explained the specific rationale for eliminating test strip funding, the move aligns with longstanding criticism from some policymakers who view harm reduction strategies as enabling continued drug use rather than promoting cessation.

Ohio's Immediate Crisis

Ohio occupies a particularly precarious position in the national overdose landscape. The state experienced some of the earliest and most devastating waves of fentanyl-involved mortality, with synthetic opioids transforming an already serious prescription opioid crisis into a catastrophe that killed thousands annually. In recent years, Ohio has also become something of a laboratory for harm reduction innovation, with cities like Columbus, Cleveland, and Cincinnati developing sophisticated distribution networks that combine fentanyl test strips with naloxone, sterile syringes, and linkage to treatment services.

Those networks now face existential disruption. The Ohio Department of Health has confirmed that multiple county health departments have suspended or significantly reduced test strip distribution as they assess remaining inventory and alternative funding options. For programs that had integrated test strips into standard outreach protocols—handing them out alongside naloxone kits and safer use supplies—the sudden absence creates operational chaos and forces difficult triage decisions about which services to prioritize.

The funding loss is particularly acute for rural counties that lacked robust local tax bases to supplement federal grants. While urban health departments in Columbus and Cleveland may have access to municipal emergency funds or foundation support, smaller jurisdictions in Appalachia and northwest Ohio have few options for replacing lost federal dollars. Some rural syringe service programs, which operated on shoestring budgets even with SAMHSA support, now face the prospect of eliminating test strip distribution entirely.

The Evidence Base Under Pressure

Fentanyl test strips represent one of the most thoroughly evaluated harm reduction interventions to emerge during the synthetic opioid era. Multiple peer-reviewed studies have demonstrated that people who use drugs modify their behavior when strips detect fentanyl presence—using smaller amounts, using with others present, ensuring naloxone is available, or in some cases choosing not to use at all. The strips do not prevent all overdoses, but they provide critical information that allows for informed decision-making in circumstances where the alternative is often blind exposure to substances of unknown potency.

The intervention is also remarkably cost-effective. At roughly one dollar per strip, the investment required to distribute them widely pales in comparison to the costs of emergency medical response, hospitalization, and long-term disability that follow non-fatal overdoses. From a purely economic perspective, eliminating test strip funding while overdose deaths remain at historically elevated levels represents a puzzling allocation of scarce public health resources.

Critics of the policy change note that it arrives precisely as the drug supply grows more dangerous and unpredictable. The emergence of ultra-potent synthetic opioids like cychlorphine—estimated to be ten times stronger than fentanyl—and the proliferation of veterinary tranquilizers like xylazine and medetomidine have made the already hazardous landscape of illicit drug use even more lethal. Test strips capable of detecting these adulterants have become essential survival tools, yet the federal government is withdrawing support for their distribution.

State and Local Responses

Ohio officials have begun exploring workarounds that might preserve some test strip access even without federal support. The state legislature is considering emergency appropriations that would redirect opioid settlement funds—payments from pharmaceutical companies found liable for fueling the addiction crisis—toward harm reduction supplies. Such a move would be legally permissible under most settlement agreements, which explicitly permit funding for overdose prevention activities, though it would require navigating complex procurement and distribution systems that SAMHSA grants had previously streamlined.

Some local health departments are turning to private philanthropy, with community foundations and corporate donors expressing interest in filling at least part of the funding gap. The sustainability of such arrangements remains uncertain, however, as philanthropic priorities shift and the long-term costs of maintaining distribution infrastructure become apparent. Federal grants had provided not just supplies but also staff positions, vehicle maintenance, and data collection systems that enabled programs to operate at scale.

Other jurisdictions are exploring regulatory workarounds, including reclassifying test strips as medical diagnostic devices that might qualify for different funding streams or seeking exceptions through state Medicaid programs. These approaches face significant bureaucratic obstacles and would require approvals from multiple federal and state agencies, creating delays that could extend the current supply gap for months.

The Broader Implications

The elimination of federal test strip funding represents more than a budgetary adjustment—it signals a fundamental philosophical shift in how the United States approaches the overdose crisis. For nearly a decade, harm reduction has occupied an increasingly central role in national strategy, supported by bipartisan recognition that abstinence-only approaches had failed to stem the tide of mortality. The SAMHSA policy change suggests that consensus may be fracturing, with federal priorities swinging back toward enforcement and treatment models that do not engage people who continue using drugs.

The consequences of this shift will not be evenly distributed. Research consistently demonstrates that harm reduction services are most heavily utilized by marginalized populations—people experiencing homelessness, those involved in criminal legal systems, and individuals without stable healthcare access. These same populations face the highest overdose risks and have the least ability to absorb disruptions in service availability. The withdrawal of federal support for test strips will likely accelerate existing disparities in overdose mortality, with consequences concentrated in communities already devastated by the crisis.

For public health practitioners who have spent years building trust with people who use drugs, the policy change threatens to undermine relationships that are essential to effective intervention. Harm reduction workers often make initial contact through the distribution of concrete supplies like test strips and naloxone, using these interactions as opportunities to offer additional services, treatment referrals, and connection to care. When those entry points disappear, so do the possibilities for engagement that might eventually lead to recovery.

Looking Forward

The coming months will test whether state and local governments can compensate for the loss of federal harm reduction funding, or whether the SAMHSA policy change will mark a turning point in national overdose trends. Early indicators from Ohio suggest the transition will be rocky, with supply disruptions and service reductions already underway. Whether these disruptions translate into increased mortality will depend on multiple factors: the speed with which alternative funding can be mobilized, the adaptability of local programs, and the underlying trajectory of the drug supply itself.

What remains clear is that the policy change arrives at a moment of genuine fragility in the overdose crisis response. After years of investment in naloxone distribution, medication-assisted treatment expansion, and harm reduction infrastructure, the United States had begun to see the first sustained declines in drug mortality since the crisis began. The elimination of federal support for fentanyl test strips represents a gamble that these gains can be maintained without one of the tools that helped produce them—a gamble that will be measured in lives lost or saved in the months ahead.